ClinicalTrials.gg
CompletedNCT04885543COVISTAUpdated May 13, 2021

COVID-19 STAndard of Care in Sub-Saharan Africa

An observational study in Covid19, sponsored by Alliance for International Medical Action. Completed at 3 sites in 2 countries. Per ClinicalTrials.gov, last updated 2021-05-13.

Sponsored by Alliance for International Medical Action · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,495
Sex
All
01

Study summary

This study was conducted in three African countries on four COVID-19 care centers (CCCs). The CCCs were set up in collaboration with a medical NGO with long experience in recording and monitoring data for cohorts and clinical trials in emergency contexts. The data were recorded using the WHO COVID-19 rapid core case report form.

02

Conditions studied

  • Covid19

Browse trials for

03

In context

COVID-19

7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.

This study's enrollment of 2,495 is above the median of 268 across 3,208 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Alliance for International Medical Action is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People hospitalized with symptomatic of COVID-19 and a positive RT-PCR SARS-CoV-2 test

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SARS-CoV-2 positive at RT-PCR

Exclusion criteria

Exclusion Criteria:

  • Asymptomatic patients
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,495 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Mortality

    In hospital mortality

    Time frame: During hospitalization, with an average of 11 days

Secondary outcomes

  1. Clinical worsening

    Combination of an SpO2 \<94% at least once during follow-up (including at baseline), use of oxygen therapy at any time during follow-up, or death

    Time frame: Hospitalization, with an average of 11 days

07

Study locations

3 sites
  • Chu Tengandogo
    Ouagadougou, BP104, Burkina Faso
  • Clinique Princesse Sarah
    Ouagadougou, BP51145, Burkina Faso
  • Chu Donka
    Conakry, BP834, Guinea
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04885543
Lead sponsor
Alliance for International Medical Action
Responsible party
Sponsor
First posted
May 13, 2021
Start date
Mar 1, 2020
Primary completion
Mar 1, 2021
Completion
Mar 1, 2021
Last update
May 13, 2021

Study contacts

Denis Malvy, Pr
principal investigator · CHU Bordeaux, INSERM 1219

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion